Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract

Completed · Phase 2 · Has a placebo group

Conditions studied: Pain, Inflammation

In brief

This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two treatment groups: N-PPDS or p-PPDS, which are inserted in the lower punctum of the subject's scheduled surgical eye. All plugs will remain in the study subject's lower punctum for a period of 2 weeks following cataract surgery.

Key facts

Study ID

NCT03496467

Run by

Mati Therapeutics Inc.

People needed

56

Starts

2018-03-05

Expected to finish

2018-12-17

Last updated by the study team

2021-10-12

Who can join

Age: 22 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A male or female subject in good general health, ≥ 22 years of age at the time of the screening visit
• A subject with a cataract for which routine phacoemulsification extraction and implantation of an intraocular lens has been planned
• A subject has a lower puncta that can be dilated to 1.0 mm in their scheduled surgical eye

You may not qualify if…

• A subject with a history of complications, adverse events, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in either eye
• A subject with structural lid abnormalities (e.g., ectropion, entropion) in their schedule surgical eye
• A subject with a puncta >0.9 mm prior to dilation in their scheduled surgical eye
• A subject with any signs of intraocular inflammation (cells/flare) in either eye at the screening visit
• A subject with a known sensitivity to nepafenac or any inactive ingredient of the punctum plug, silicone, fluorescein, topical anesthetic, or any other products required for study procedures or cataract surgery
• A subject with a history of chronic/recurrent inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis) in either eye

Where it is running

• Cincinnati Eye Institute-Edgewood — Edgewood, Kentucky, United States
• Ophthalmic Consultants of Long Island — Garden City, New York, United States
• Kerry Solomon, MD — Mt. Pleasant, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.